9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice

Clinical Cancer Research

Volumn 6, Issue 7, 2000, Pages 2876-2880

  Koshkina, Nadezhda V ^a   Kleinerman, Eugenie S ^b   Waldrep, Clifford ^a   Jia, Shu Fang ^b   Worth, Laura L ^b   Gilbert, Brian E ^a   Knight, Vernon ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RUBITECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG TISSUE LEVEL; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CAMPTOTHECIN; DRUG CARRIERS; FEMALE; HUMANS; LIPOSOMES; LUNG; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; OSTEOSARCOMA; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0033911323     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Gilbert, B. E., and Knight, V. Pulmonary delivery of antiviral drugs in liposome aerosols. Semin. Pediatr. Dis., 7: 148-154, 1996.
2. Waldrep, J. C., Gilbert, B. E., Knight, C. M., Black, M., Scherer, P. W., Knight, V., and Eschenbacher, W. Pulmonary delivery of beclomethasone liposome aerosol in volunteers: tolerance and safety. Chest, 111: 316-323, 1997.
3. Knight, V., Koshkina, N. V., Waldrep, J. C., Giovanella, B. C., and Gilbert, B. E. Anti-cancer effect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice. Cancer Chemother. Pharmacol., 44: 177-186, 1999.
4. Koshkina, N. V., Gilbert, B. G., Waldrep, J. C., Seryshev, A., and Knight, V. Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice. Cancer Chemother. Pharmacol., 44: 187-192, 1999.
5. Jia, S-F., Worth, L. L., and Kleinerman, E. S. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin. Exp. Metastasis, 17: 501-506, 1999.
6. Phalen, R. F. Inhalation Studies: Foundations and Techniques. Boca Raton, FL: CRC Press, Inc., 1984.
7. Giovanella, B. C., Natelson, E., Harris, N., Vardeman, D., and Stehlin, J. S. Protocols for the treatment of human tumor xenografts with camptothecins. Ann. N. Y. Acad Sci., 803: 181-186, 1996.
8. Pantazis, P., Kozielsky, A. J., Vardeman, D. M., Petry, E. R., and Giovanella, B. C. Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol. Res., 5: 273-281, 1993.
9. Thompson, J., Stewart, C. F., and Houghton, P. J. Animal models for studying the action of topoisomerase I targeted drugs. Biochim. Biophys. Acta, 1400: 301-319, 1998.
10. Patton, J. C. Mechanisms of macromolecule absorption by the lungs. Adv. Drug Delivery Rev., 19: 3-36, 1996.
11. Fairchild, G. A. Measurement of respiratory volume for virus retention studies in mice. Appl. Microbiol., 24: 812-818, 1972.
12. Thomas, R. L. Deposition and initial translocation of inhaled particles in small laboratory animals. Health Phys., 16: 417-428, 1969.
13. Verschraegen, C. F., Natelson, E. A., Giovanella, B. C., Kavanagh, J. J., Kudelka, A. P., Freedman, R. S., Edwards, C. L., Ende, K, and Stehlin, J. S. A Phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor. Anti-cancer Drugs, 9: 36-44, 1998.
14. Farr, S. J., Kellaway, I. W., Parry-Jones, D. R., and Woolfrey, S. G. 99m-Technetium as a marker of liposomal deposition and clearance in the human lung. Int. J. Pharm., 26: 303-316, 1985.
15. Vidgren, M., Waldrep, J. C., Arppe, J., Black, M., Rodarte, J. A., Cole W., and Knight V. A study of 99mtechnetium-labelled beclomethasone dipropionate dilauroylphosphatidylcholine liposome aerosol in normal volunteers. Int. J. Pharm., 115: 209-216, 1995.
16. Morimoto, Y., and Adachi, Y. Pulmonary uptake of liposomal phosphatidylcholine upon intrathecal administration to rats. Chem. Pharm. Bull., 30: 2248-2251, 1982.
17. Verschraegen, C., Gilbert, B. E., Huaringa, A., Newman, R., Harris, N., Leyva, F., Keus, L., Campbell, K., Nelson-Taylor, T., Vincent, M., and Knight, V. Feasibility, Phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(s)-camptothecin (L9NC) in patients with advanced malignancies in the lungs. Proc. Am. Assoc. Clin. Oncol., 904: 231a, 2000.